Braeburn Pharmaceuticals IPO Research Information

Braeburn Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Braeburn Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Braeburn Pharmaceuticals	BBRX - NASDAQ	TBD	$0.00	$0.00	TBD
Underwriter(s): J.P. Morgan, BofA Merrill Lynch, Deutsche Bank Securities
Co-Manager(s): Canaccord Genuity
Industry:
Filing(s): Filed 2016-12-30 Terms Added 2017-01-18

About Braeburn Pharmaceuticals (adapted from Braeburn Pharmaceuticals prospectus):
They are a commercial-stage pharmaceutical company focused on the development and commercialization of novel long-acting medications for serious disorders of the central nervous system, or CNS.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "BBRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.